Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis

Int J Mol Sci. 2022 May 5;23(9):5146. doi: 10.3390/ijms23095146.

Abstract

The emerging issues nowadays are non-alcoholic fatty liver disease (NAFLD) and its advanced stage non-alcoholic steatohepatitis (NASH), which further can be a predisposing factor for chronic liver complications, such as cirrhosis and/or development of hepatocellular carcinoma (HCC). Liver lipotoxicity can influence the accumulation of reactive oxygen species (ROS), so oxidative stress is also crucial for the progression of NASH. Moreover, NASH is in strong connection with metabolic disorders, and supporting evidence shows that insulin resistance (IR) is in a close relation to NAFLD, as it is involved in the progression to NASH and further progression to hepatic fibrosis. The major issue is that, at the moment, NASH treatment is based on lifestyle changes only due to the fact that no approved therapeutic options are available. The development of new therapeutic strategies should be conducted towards the potential NAFLD and NASH treatment by the modulation of IR but also by dietary antioxidants. As it seems, NASH is going to be the leading indication for liver transplantation as a consequence of increased disease prevalence and the lack of approved treatment; thus, an effective solution is needed as soon as possible.

Keywords: NAFLD; NASH; lipids; liver; metabolism.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular* / metabolism
  • Disease Progression
  • Humans
  • Insulin Resistance*
  • Liver / metabolism
  • Liver Cirrhosis / pathology
  • Liver Neoplasms* / metabolism
  • Non-alcoholic Fatty Liver Disease* / metabolism

Grants and funding

This research received no external funding.